Physician profile
Lin Clark
NPI 1770044570
$1,486.36
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $160 · 2022: $547 · 2023: $708 · 2024: $71.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.09 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $489.12 | 2022-2023 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $203.83 | 2022-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $175.63 | 2021-2023 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $114.85 | 2021-2022 | |
| Abbvie INC. | $109.30 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.73 | 2023-2024 | Caplyta |
| Idorsia Pharmaceuticals US INC | $79.04 | 2022-2023 | Quviviq |
| Alkermes, INC. | $75.10 | 2022 | |
| Lundbeck LLC | $52.80 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $35.27 | 2021-2022 | |
| Axsome Therapeutics, INC. | $31.54 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $14.15 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.